Fatty Liver Disease (MASH) and Type 2 Diabetes: How to Protect Your Liver
In this 5-minute video, Dr. Steve Edelman and Dr. Jeremy Pettus from Taking Control Of Your Diabetes (TCOYD) explain the critical connection between diabetes and fatty liver disease, a condition that affects up to 60% of people with type 2 diabetes – often without any noticeable symptoms. Learn what Metabolic Dysfunction-Associated Steatohepatitis (MASH) is, how it progresses, and why early detection is vital.
Discover the importance of weight management and current treatments that were recently approved by the FDA (like GLP-1 agonists and Rezdiffra) in preventing and treating MASH. We discuss the risks of liver fibrosis, cirrhosis, and liver cancer, and provide actionable steps to take control of your liver health. Don’t let fatty liver disease impact your life expectancy! Watch now to learn how to proactively manage your diabetes and protect your liver.
WANNA KEEP GOING? LEARN MORE WITH US!
Diabetes and Fatty Liver Disease:
Featuring Dr. Juan Pablo Frias
Diabetes and Fatty Liver Disease: Featuring Dr. Juan Pablo Frias
In this podcast episode, Dr. Steve Edelman and Dr. Jeremy Pettus dive into a little-known but critical complication of diabetes—fatty liver disease. They are joined by Dr. Juan Pablo Frias, an endocrinologist and metabolic disease expert, to explore why people with diabetes are at significantly higher risk of developing fatty liver and what can be done to prevent, detect, and treat it before it leads to serious complications. They discuss the direct connection between insulin resistance, obesity, and liver health, the silent progression of fatty liver disease, and why liver health should be a key part of diabetes management. The episode also highlights how diabetes medications like GLP-1 receptor agonists (Ozempic, Mounjaro) and SGLT2 inhibitors may help protect the liver in addition to their benefits for blood sugar, heart, and kidney health.
MASLD and MASH: Liver Conditions that Can Affect People with Diabetes
MASLD is characterized by fat deposition in the liver without liver injury. MASH is a later-stage condition with both fat deposition and liver cell injury. MASH has a higher risk of progression to end-stage liver scarring (cirrhosis), as well as liver cancer (hepatocellular carcinoma). Early detection is key to preventing and slowing the progression of liver disease. MASLD and MASH often do not have noticeable symptoms, so if you have risk factors such as obesity, hypertension, insulin resistance, and/or high cholesterol, talk to your doctor about being tested. Lifestyle modifications play a vital role in preventing and managing the conditions, as well as benefiting overall health.
Very informative and these men are very easy to listen to.
Thanks Karen – appreciate it!
Great, informative video. I have a friend who was diagnosed with fatty liver disease and it’s a type two diabetic. I’m sending this to her to listen to. Thank you so much for putting this out there.
Jane.
You’re so welcome. Glad you found it helpful, and thank you for sharing it with your friend.
Very helpful. Wish I had been given this information much sooner.
Thank you again!
You’re so welcome, Mary!
Very informative talk . I hope to watch more on this subject. Medicare won’t let Seniors afford Resdiffa not spelled right. .I’m sad about that. Because I need to take this.
I was diagnosed with NASH in 2011 at that time drs told me it was nothing to be concerned about. In 2024 diagnosed with cirrhosis…under drs care for yrs …my PCP always said my labs were good …went to my yearly oncologist appointment he ordered my CT SCAN…the results showed cirrhosis…from there biopsy, fibro scan ,ultrasound,..I pick up old labs from PCP liver function test were all HIGH…